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Abstract 
Competitive inhibition diminishes ligand adhesion as receptor sites become occupied with 
competing ligands. It is unknown if this effect occurs in ultrasound molecular imaging studies where 
endothelial binding sites become occupied with adherent bubbles or bubble fragments. The goal of 
this pilot study was to assess the effect that repeated administration and clearance of targeted 
agents has on successive adhesion. Two groups of animals were imaged with 3-D ultrasonic mo-
lecular imaging. Injections and imaging were performed on Group 1 at time 0 and 60 minutes. 
Group 2 received injections of microbubbles at 0, 15, 30, 45 and 60 minutes with imaging at 0 and 
60 minutes. At 60 minutes, Group 1 targeting relative to baseline was not significantly different 
from Group 2 (1.06±0.27 vs. 1.08±0.34, p=0.93). Data suggest that multiple injections of targeted 
microbubbles do not block sufficient binding sites to bias molecular imaging data in serial studies. 
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Introduction 
Molecular imaging with ultrasound is a modal-
ity, which is gaining interest in preclinical and clinical 
studies because it extends the ability to assess molec-
ular changes to the already low-cost, non-ionizing, 
real-time, and widely available modality of ultra-
sound. The principle behind ultrasonic molecular 
imaging is the selective adherence of microbubble 
contrast agents to biomarkers expressed on the en-
dothelium [1, 2, 3]. Once the contrast agents accumu-
late at the target site, they enhance the pathologic 
tissue via increased acoustic backscatter, thus 
providing indication of the presence of biomarkers 
associated with disease [4]. This approach enables the 
ability to evaluate biological changes at the molecular 
level (ex. angiogenic expression) before phenotypic 
changes occur [4, 5]. Thus, this technique is well 
suited for theranostic applications such as monitoring 
response to therapy, which may ultimately lead to a 
more personalized approach to medicine [6, 7, 8]. 
Often, an ultrasonic molecular imaging study 
requires multiple targeted microbubble injections 
within a single imaging study to evaluate short-term 
biological changes, system parameters, or novel mi-
crobubble formulations [9, 10, 11, 12]. Targeted mi-
crobubbles are fitted with a ligand that allows binding 
to endothelial biomarkers. However, as endothelial 
receptors are occupied by ligands from targeted bub-
bles, it is probable that these receptors would no 
longer be available for future targeting. This might 
happen if either bubbles stay retained at the target 
site, or if fragments of the bubbles are retained at the 








microbubbles are injected multiple times in a single 
animal study, it is possible that the quantity of avail-
able binding sites is diminished over time. In the case 
where receptor ligands were sufficiently competi-
tively inhibited, it would bias the results of successive 
molecular imaging data where multiple targeted mi-
crobubble injections are required. 
We hypothesized that the amount of biomarker 
expression, relative to the amount of receptors occu-
pied by ligands from targeted bubbles, would be great 
enough to allow for multiple targeted microbubble 
injections for a single animal study without discerni-
ble competitive inhibition effects. To test this hy-
pothesis, we analyzed the in vivo molecular imaging 
results from two groups of animals. The first group of 
animals, a control group, received molecular imaging 
studies with microbubbles targeted to αvβ3 at time 0 
and 60 minutes. The second group of animals was 
imaged at the same two time points, but with three 
additional targeted microbubble injections at time 15, 
30, and 45 minutes (Figure 1). These time points were 
chosen to provide sufficient time for microbubbles to 
clear circulation prior to successive injections. Molec-
ular imaging results were compared between groups 
at baseline and 60 minutes as an indication of whether 
or not multiple serial injections have an effect on the 
outcome of an ultrasonic molecular imaging experi-
ment.  
Materials and Methods 
Microbubble Preparation 
Microbubbles designed to target αvβ3 integrins 
were created with a 9:0.5:0.5 molar ratio of 1,2 Dis-
tearoyl- sn-Glycero-3-Phosphocholine (DSPC) (Avanti 
Polar Lipids, Alabaster, AL, USA), 1,2-Distearoyl- 
sn-Glycero-3-Phosphoethanolmine-N–Methoxy-Polye
thylene Glycol-2000 (DSPE-PEG2000) (Avanti Polar 
Lipids, Alabaster, AL, USA), and DSPE-PEG2000 
cross-linked to a cyclic RGD peptide (Cy-
clo-Arg-Ala-Asp-D-Tyr-Cys) (Peptides International, 
Louisville, KY, USA) as previously described [13]. The 
cyclic RGD peptide has previously been shown to 
target αvβ3-expressing vasculature, which is charac-
teristic of angiogenic tumors [14, 15]. Competitive 
inhibition with free RGD shows reduction in adhesion 
to αvβ3 suggesting, some degree of specificity [16]. 
Microbubbles with a large preferentially selected 
mean diameter (~3.9 µm) have been shown to pro-
duce greater backscatter intensities in molecular im-
aging studies as compared to vial-shaken unsorted 
polydisperse distributions [13, 17]; therefore, all mi-
crobubbles in this study were size-selected via the 
method described by Feshitan and colleagues [18].  
 
 
Figure 1. The timelines for when bolus injections were given and the imaging readpoints for groups 1 and 2. Each bolus injection, for 
group 1 and group 2, consisted of a contrast agent dose of 5 x 106 microbubbles. 
 




Animals and Tumor Models 
A total of 13 Fischer 344 rats (Charles River La-
boratories, Durham, NC, USA) of similar sizes (~125 
g) were used for all in vivo studies (Group 1 - N = 7, 
Group 2 – N = 6). All animal studies were conducted 
in accordance with the protocols approved by the 
University of North Carolina School of Medicine’s 
Institutional Animal Care and Use Committee. 
The tumor model used in all in vivo experiments 
was a rat fibrosarcoma [19]. In previous studies, this 
particular type of tumor has been shown to provide a 
good model for αvβ3 targeted molecular imaging [13, 
20].  
Animal Preparation and contrast administra-
tion 
Rodents were anesthetized for in vivo molecular 
imaging studies with ~2% inhaled isoflurane mixed 
with oxygen. Once the rat was sedated, the area to be 
imaged was shaved with small animal hair clippers 
and further depilated using a chemical hair remover. 
A 24-gauge catheter was inserted into the tail vein of 
the animal for the purpose of administering mi-
crobubble contrast agents. The ultrasound transducer 
used in the in vivo analysis was positioned in a fixed 
clamp and coupled to the animal with ultrasound gel. 
Throughout the imaging procedure, the rodent’s body 
temperature was maintained through the use of a 
temperature-controlled heating pad. 
The sizes and concentrations of stock solutions 
for all microbubble types used in this study were 
measured prior to each imaging study using an Ac-
cusizer 780A laser light obscuration and scattering 
device (Particle Sizing Systems, Santa Barbara, CA, 
USA). For each injection, the appropriate volume of 
stock solution was added to the catheter via a mi-
cropipette tip and flushed with 100 μL of sterile saline 
such that a contrast agent dose of 5 x 106 microbubbles 
was administered consistently with each injection. 
Animals received less than 1.5 mL of total fluid vol-
ume within any 24-hour period. 
Clinical Imaging System 
An Acuson Sequoia 512 ultrasound imaging 
system (Siemens, Mountain View, CA, USA) was used 
to acquire all images in this study. B-mode images 
were collected at 14 MHz using a 15L8 linear array 
transducer in spatial compounding mode as a means 
for selecting the regions of interest in each image 
plane. Microbubble contrast agents were imaged in 
Cadence Pulse Sequencing mode, which is nonde-
structive when a low MI is used [21].  
To create 3-D datasets, the transducer was 
stepped elevationally across the tumor using a Lab-
View (National Instruments, Austin, TX, USA) con-
trolled motion stage (Newport, Irvine, CA, USA) as 
previously described [22].  
Molecular Imaging Protocol 
Molecular imaging data was obtained after 
freely circulating microbubbles had visibly cleared the 
animal’s system (typically ~10 minutes). Once the 
microbubbles had cleared, one image frame of video 
data in Cadence Pulse Sequencing mode (7 MHz, MI: 
0.18, dynamic range: 80 dB) was collected at every 400 
µm as the transducer was stepped across the tumor. 
Next, the imaging system was set to a microbub-
ble-destructive setting with a center frequency of 7 
MHz and a mechanical index of 1.9. Subsequently, the 
transducer was swept at 1 mm/sec elevationally 
across the tumor to destroy any adherent microbub-
bles remaining in the vasculature. Prior studies uti-
lizing a MI of 1.9 to destroy microbubbles suggest the 
absence of bioeffects at higher frequencies such as 7 
MHz utilized in this study [23]. Finally, the system 
was again set to image in Cadence Pulse Sequencing 
mode and the tumor was re-imaged at each location 
across the tumor to collect background image inten-
sity data. This baseline image set allowed us to de-
termine the background signal for quantifying the 
biomarker expression. Within all imaging data sets, 
the gain (-10 dB) and transmit power (MI: 0.18) were 
kept constant. In a prior study, the video intensity of 
targeted agents retained in vivo was observed over 30 
seconds using Cadence Pulse Sequencing mode at a 
mechanical index of 0.18, and no loss in signal inten-
sity was observed while imaging adherent targeted 
contrast agents, indicating that our imaging parame-
ters were largely nondestructive (data not shown).  
Molecular Imaging Analysis 
Video data was saved from the imaging system 
in DICOM format and analyzed using custom 
MATLAB software (Mathworks, Natick, MA, USA). 
Volumetric intensities were obtained by summing all 
of the pixel intensity values for each voxel within the 
drawn regions of interest and dividing that value by 
the total number of voxels within the volume. As with 
previous molecular imaging studies, the intensity 
brightness was assumed to be correlated with the de-
gree of αvβ3 expression [9, 20, 24, 25, 26]. Final values 
for biomarker expression for each microbubble type 
were computed by subtracting the background vol-
umetric intensity from the volumetric intensity pro-
duced by the adherent microbubbles. We used 
MATLAB’s two-sided student's t-test to assess the 
statistical significance of our group. Significance be-




tween two different distributions were considered at a 
value of p < 0.05. 
Results  
Two different groups of animals were imaged 
with ultrasonic molecular imaging to determine if 
multiple serial injections affect the amount of adher-
ent microbubbles detected in an individual experi-
ment. Intensity values for each animal’s readpoint 
were normalized to the value at the baseline meas-
urement or time 0. Injections and molecular imaging 
readpoints were performed on the control group 
(Group 1) at time 0 and 60 minutes after the first in-
jection while Group 2’s injections were at times 0, 15, 
30, 45 and 60 minutes with readpoints at 0 and 60 
minutes. 
Group 1 showed a 6% increase (1.06±0.27) in 
targeting relative to baseline while Group 2 showed 
an 8% increase (1.08±0.34) in the amount of targeted 
microbubbles, as determined through intensity 
measurements (Figure 2). Group 1 was not signifi-
cantly different from Group 2 after the 60-minute 
readpoint (p = 0.93), but rather had similar targeting 
and similar variance. Figure 3 shows a 2 by 2 panel of 
a representative Group 1 tumor and a representative 
Group 2 tumor at baseline and 60 minutes after. The 
green color represents the targeted microbubble sig-
nal detected via Cadence Pulse Sequencing mode in 
the experiment. The green pixels, correlated to the 
degree of αvβ3 expression, are overlaid onto a tradi-
tional B-mode image to illustrate the location of the 
targeting relative to the tumor.  
 
 
Figure 2. The percent change in volumetric targeted mi-
crobubble intensity for Groups 1 and 2, 60 minutes after baseline 
imaging. p = 0.93 for Group 1 relative to Group 2. 
 
Figure 3. 2 - D  ultrasound images of a representative Group 1 and Group 2 tumor (selected from a 3-D dataset) at baseline and 60 
minutes after initial imaging. The green color is the targeted microbubble signal detected via Cadence Pulse Sequencing mode. The 
intensity of the green color is loosely correlated to the degree of αvβ3 expression. The green signal is overlaid onto a traditional B-mode 
image to illustrate the location of the targeting relative to the tumor. The white dotted line illustrates the region of interest selected for 
the quantification of biomarker expression. 




Discussion and Conclusion 
In this study, we evaluated if successive injec-
tions of targeted microbubbles would reduce the abil-
ity of future injections of targeted bubbles to adhere to 
endothelial receptor ligands. While the scope of this 
study was limited to a short time period, as well as a 
specific tumor model, and a specific microbubble 
dose, the results are encouraging. Given the dose of 
cRGD-targeted microbubbles injected (which was 
appropriate for achieving sufficient molecular imag-
ing signal) and the inherent variability of the molec-
ular imaging procedure, there was no discernible sta-
tistical difference between injecting twice and inject-
ing five times. Ultimately, this suggests that the 
quantity of over-expressed αvβ3 biomarkers present 
must be sufficiently greater than the available ligands 
so as not to present competitive inhibition. Thus, pre-
liminary data suggests that serial multiple injections 
in a single ultrasonic molecular imaging study, do not 
bias or compromise endothelial retention of targeted 
microbubbles due to competitive inhibition from prior 
bound bubbles or bubble fragments. This result 
would be important in theranostics assays involving 
serial ultrasound molecular imaging exams. What our 
study does not address is whether or not the adhesion 
of targeted bubble ligands affects the tumor biology, 
as might be anticipated with large doses. Further-
more, we observed a slight increase in molecular tar-
geting in both imaging models, the mechanism for 
which is still unknown. Future studies beyond this 
pilot should include larger animal numbers, different 
doses of contrast, different ligands, and longer time 
points.  
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